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RESUMO 
Ciclosporina A é a principal droga imunossupressora utilizada na 
prevenção da rejeição de transplantes. Esta droga induz inúmeros efeitos 
colaterais, incluindo o aumento gengiva/ observado em 8 a 70% dos pacientes 
em tratamento com a droga. Embora a patogênese dos aumentos gengivais 
seja desconhecida, recentemente foi demonstrado que ciclosporina A induz a 
expressão do fator de crescimento transformante-beta1 (TGF-81). O objetivo 
deste trabalho foi investigar o papel de TGF-81 na patogênese do aumento 
gengiva/ induzido por ciclosporina A, explorando um possível efeito autócrino 
deste fator na proliferação celular e na expressão de meta/oproteinases de 
matriz (MMPs) e seus inibidores teciduais (TIMPs). Para determinar o efeito de 
ciclosporina A na expressão e produção de TGF-81, culturas primárias de 
fibroblastos gengívais humanos normais foram tratadas com concentrações 
crescentes de cíclorporina A por 24 h, e os níveis de expressão e produção de 
TGF-{31 analizados por pelo método semi-quantitativo da transcriptase 
reversa-reação em cadeia da polimerase (RT-PCR) e EUSA, respectivamente. 
Os efeitos de ciclorporina A e TGF-{31 na proliferação de fibroblastos gengívais 
foram analisados através de 4 ensaios de proliferação celular, incluindo ensaio 
de crescimento celular, análise da incorporação de bromodeoxiuridina (8rdU), 
quantificação da expressão imunohistoquímica do antígeno nuclear de 
proliferação celular (PCNA) e potencial mitótico. O efeito de cíclosporina A na 
expressão de MMP-1, MMP-2, TIMP-1 e TIMP-2 foram determinados por RT-
PCR. Para determinar o efeito autócrino de TGF-81 na proliferação celular e na 
expressão de MMPs e TIMPs, nós utilizamos oligonucleotides complementares 
a região de iniciação da tradução de TGF-81. Ciclosporina A, em níveis 
similares aos encontrados no sangue de pacientes em uso da droga, 
significantemente estimulou a expressão de produção de TGF-81. De uma 
maneira similar, ciclosporina A estimulou a proliferação celular e inibiu a 
expresao de MMP-1 e MMP-2 por fibroblastos gengivais. Os níveis de TIMP-1 e 
TIMP-2 foram inalterados pelo tratamento com ciclorporina A. O tratamento 
com ciclosporina A em combinação com o bloqueio na produção de TGF-/31 por 
ofigonucleotideos complementares reduziu os efeitos de ciclosporina A na 
proliferação celular e na expressão de MMP-1 e MMP-2 por fibroblastos 
gengivais. Nossos resultados demonstram que ciclosporina A induz a 
expressão TGF-/31 em fibroblastos gengivais, o qual de uma maneira autocrina 
exacerba a proliferação e reduz a expressão de MMPs em fibroblastos 
gengivais normais. 
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Abstract 
Cyclosporin A (CyA) is a widely used immunosuppressant which 
possesses significant side effects including gingival overgrowth. The 
pathogenesis of this condition is not fully understood. However, recent studies 
showed that CyA regulates the transcription of severa/ cytokines including 
transforming growth factor-beta1 (TGF-/}1). The aim of this study was to 
analyze the potential role of TGF-81 in the pathogenesis of CyA-induced 
gingiVal overgrowth. We hypothesíze that TGF-{31 is an important autocríne 
regulator of ce/1 proliferation, synthesis of matrix metalloproteinases (MMPs) 
and its tíssue inhibitors TIMPS in the experimental settings of CyA induced 
gingiVal overgrowth. 
To test these hypothesis gingival fibroblasts (GF) from normal gingiva 
were incubated with increasing concentrations of CyA and the expression and 
production of TGF-81 determined by RT-PCR and ELISA. Proliferative activity 
of CyA-treated GF was studied by growth curve (via ce/1 countíng), BrdU 
incorporation, quantification of PCNA and mitotic potential. MMPs expression 
leveis were analyzed by RT-PCR. To determine the effects of TGF-81 on the 
proliferation rate and on the expression of MMPs by GF under CyA treatment, 
the cells were incubated with CyA and antisense oligonucleotides (AON) 
against the TGF-81 mRNA. 
CyA simultaneously stimulated TGF-81 expression, increased 
proliferation and inhibited expression of MMP-1 and MMP-2 with a slight effect 
on TIMP-1 and TIMP-2 expressíons. 8oth CyA and TGF-{31 stimulated 
significantly the proliferation of GF in a dose-dependent manner. When TGF-81 
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was inhibited using specific antisense oligonucleotides (AON) a reduced TGF-
{31 production was noticed (demonstrated by EUSA) with no significant effect 
on the mRNA leveis. When cells were treated with AON simultaneously with 
CyA, the effects of CyA on proliferation and expression of MMPs were 
neutralized, the original proliferation rate and MMPs expression were restored. 
Our investigation of the molecular events that lead to CyA-induced 
gingival overgrowth showed that TGF-81 in an autocrine fashion upregulates 
proliferation and downregulates expression of MMPs, which may underlie the 
clinicai changes associated with CyA treatment. 
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1.. INTRODUÇÃO 
Aumento gengiva/ é um termo genérico usado clinicamente para 
identificar uma alteração volumétrica da gengiva, frequentemente resultado 
do acúmulo excessivo de grandes quantidades de tecido conjuntivo fibroso. O 
aumento gengiva/ pode ser iatrogêníco, idiopático, inflamatório, 
medicamentoso ou hereditário (Takagi et a/., 1991). No caso dos aumentos 
gengivais medicamentosos, os bloqueadores dos canais de cálcio: ciclosporina 
A, fenítoína e nifedípína são as drogas mais associadas. 
Os aumentos gengívaís estão certamente fígados a um desequilíbrio nos 
mecanismos bíologicos locais, o que pode envolver: aumento na síntese ejou 
diminuição na degradação de matriz extrace/u/ar; aumento na proliferação 
celular local (fibroblastos gengívais); ou provavelmente ambos, levando a um 
desequilíbrio generalizado no controle de síntese e degradação da matriz 
extracelufar e na proliferação celular, o que é controlado por moléculas 
sinalizadoras como por exemplo o fator de crescimento transformante f31 
(TGF-1). (Barto/d PM 1989; Bo/tchi et a/, 1999) 
A Ciclosporina A é uma molécula cíclica e hidrófoba composta por onze 
aminoácidos com alta capacidade imunossupressora. Esta molécula é o 
produto metabólico de dois fungos, To/ypocladíum ínflatum e Cylindrocarpon 
lucidum (Borel et. AI., 1976). Embora apresente funções antífúngicas e 
antibacterianas, a principal indicação terapêutica de ciclosporina A esta 
relacionada com a função imunossupressora, por bloquear a síntese de 
inter/eucina 2 e outras citocinas em linfócitos T, sendo amplamente utilizada 
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na prevenção da rejeição de transplantes e no tratamento de doenças 
autoimunes (Kanitakis e Thivo/et, 1990). 
A ciclosporina A pode promover uma série de efeitos colaterais que 
estão relacionados principalmente com variações na absorção e metabolismo 
da droga e com a susceptibilidade individual. Dentre estes efeitos colaterais 
podemos listar: nefro, hepato e neurotoxicidade, hipertensão arterial, indução 
de cálculos biliares, diabetes, alteração no metabolismo ósseo e hirsutismo, 
além de infecções oportunistas associadas indiretamente à droga (Ota e 
Bradley, 1983; Goldman et. ai. 1985; O'valle et. a/. 1994). Para a área 
odontológica, os efeitos colaterais mais importantes são a hipertrofia das 
papilas linguais fungiformes e o aumento gengiva/ (Silverberg et e/. 1996; 
Marsha/1 and Bartold, 1998). A média de incidência de aumento gengiva! em 
pacientes tratados com ciclosporina A é de 25%, com uma variabilidade de 8 
'a 70% (Seymour and Heasman 1988). De modo interessante, estudos que 
utilizam doses e tempo de duração de tratamento maiores mostram uma 
incidência de 70%. Acredita-se que esta variação dependenda de 
susceptibilidade genética, duração e dose da droga, além das concentrações 
séricas e salivares (Marsha/1 and Bartold, 1988). Um programa de remoção e 
controle de placa pode melhorar as condições gengivais mas não impede a 
evolução do aumento gengiva! (Seymour & Jacobs, 1992). Já a redução da 
dose de ciclosporina A se mostra efetiva no não desenvolvimento do aumento 
gengiva! (Daly, 1992). 
Clinicamente o aumento gengiva/ induzido por cic/osporina A se 
apresenta como lesões nodulares fibróticas comumente restritas a gengiva 
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aderida, mas podendo se estender para a gengiva livre, interferindo nos 
movimentos fisiológicos de oclusão, mastigação e fonação, além de problemas 
estéticos. Histo/ogicamente, o aumento gengiva! apresenta uma mucosa 
recoberta por epitélio pavimentoso estratificado hiperplásico e com múltiplas e 
longas criptas epiteliais. No tecido conjuntivo subjacente observa-se 
acentuado acúmulo de fibras colágenas permeadas por fibroblastos, vasos 
sangüíneos e ocasionais células inflamatórias (Rostock et a/, 1986; Wondimu 
et ai, 1993). 
Observações em estudos de culturas celulares, apesar de variáveis, 
demonstram que fibroblastos gengivais na presença de cic/osporina A 
apresentam um alterado comportamento proliferativo, um desequilíbrio na 
relação síntese e degradação de matriz extracelular e um aumento na 
produção de moléculas sinalizadoras e reguladoras destes processos. (Me/ler 
et ai., 2002; Spolidorio et a/. 2002) Existem evidências na literatura de que a 
indução de TGF-81 pelo tratamento com ciclosporina A pode ser o principal 
fator relacionado com os efeitos colaterais da droga (Pascual et ai., 1998; 
Khanna et ai., 1998) incluindo a hiperplasia gengiva! (Silverberg et ai., 1996; 
Marsha/1 and Bartold, 1998). Contudo, o mecanismo da participação de TGF-
{31 nos aumentos gengivais, especialmente os causados pela cic/osporina A, 
permanece incerto. 
Foi demostrado que ciclosporina A estimula a produção de TGF-1 in vitro 
em linfócitos T humanos, linhagens celulares de células provenientes do túbulo 
proximal de camundongos e fibroblastos tubulointersticiais (Shin et ai., 1998), 
e in vivo em rim de ratos e camundongos (Waiser J et ai .. 2002). Este mesmo 
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aumento na expressão de TGF-{31 roi também encontrado em células renais de 
pacientes transplantados tratados com CyA (Campistol J.M., et ai 2001). 
TGF-{31 tem sido considerado uma citocina fibrogenética chave na patogênese 
da nefropatia alográfica crônica, a principal causa de insucesso tardio de 
transplantes renais. Independente dos eventos que podem desencadear este 
processo, a nefropatia alográfica crônica está relacionada principalmente a 
fibrose ou acúmulo de matriz extracelular (glomeru/ar, arteriolar e intersticial) 
regulada por TGF-/31 (Campistol J.M., et a/2001; Waiser J et ai, 2002). 
Bartold (1989), mostrou que ciclosporina A estimula a síntese de DNA e 
a proliferação de fibroblastos gengívais in vitro mesmo sem a adição de soro 
fetal bovino as culturas celulares. Neste mesmo estudo ciclosporina A foi 
utilizada em conjunto a lipopolissacarideos, em concentrações que 
normalmente inibiriam a proliferação dos fibroblastos gengivais, ainda assim a 
ciclosporina A reteve sua capacidade de estimular a proliferação celular. Em 
tecido gengiva!, Bolzani et a/. mostraram que cic/osporina A, em 
concentrações similares as concentrações séricas de pacientes sob tratamento 
com droga, inibe significativamente a produção de MMP-1 e MMP-3, alem de 
diminuir a atividade gelatinolítica de MMP-2. Coletta et ai (1999}, 
demostraram que a elevada expressão de TGF-{31 em fibroblastos gengivais de 
pacientes com fibromatose gengiva/ hereditária induz a redução nos níveis de 
expressão de MMP-1 e MMP-2, levando a um acúmulo de matriz extracelular. 
Hyland et ai. (2003) mostraram recentemente que ciclosporina A em linhagens 
celulares de fibroblastos gengivais inibe significativamente os níveis de MMP-1. 
Em um artigo de revisão da literatura Boltchi et a! (1999), relatam o aumento 
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na expressão de TGF-{31 e PDGF (fator de crescimento derivado de plaquetas), 
como os possíveis responsáveis pelo maior índice pro/iterativo e aumento na 
síntese de matriz extracelular em fibroblastos gengivais sob a influência de 
ciclosporina A. 
TGF-/3 foi originalmente purificada da placenta humana, plaquetas e rim 
bovino (Roberts et ai, 1984). A denominação fator de crescimento 
transformante {TGF) é devido à habilidade deste fator permitir que células 
normais cresçam em soft agar, uma característica exclusiva de células 
malignas, e por causar transformações fenotípicas em fibroblastos (Roberts et 
ai., 1981; Tucker et ai., 1983). O gene que codifica TGF-[31 esta localizado no 
19q13, praticamente todos os tipos celulares apresentam receptores para 
TGF-[3, sendo assim seu papel tanto fisiológico, quanto no desenvolvimento de 
patologias extenso (Fianders and Roberts, 2000). TGF-j3 regula muitos 
processos que são comuns tanto para o reparo tecidual quanto para o 
desenvolvimento de algumas doenças, incluindo angiogênese, quimiotoxia de 
fibroblastos, linfócitos, macrófagos e neutrófilos; proliferação de fibroblastos, 
controle de diferenciação celular, apoptose e o controle da síntese e 
degradação das proteínas que constituem a matriz extrace/ular, como 
colágenos, fibronectinas e proteoglicanos. (Govinden and Bhoola 2003; Ignotz 
and Messangue, 1986: Raghow et ai., 1987; Laiho and Keski-Oja, 1989; 
Overa/1 et a!., 1989). Desde a definição inicial de TGF-[3 em 1983, mais de 40 
membros diferentes da família TGF-/3 foram descritos em espécies que vão da 
alga marinha aos humanos. Todas essas proteínas têm em comum a 
característica básica de serem formadas por um centro composto por sete 
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moléculas de cisteina. Em humanos encontramos 3 isoformas, o original 
descrito TGF-(3 que foi posteriormente chamado de TGF-(31 além de TGF-(32 e 
TGF-(33, todos sendo secretados como homodímeros na forma latente 
(Fianders and Roberts, 2000). As alterações que TGF-(31 pode causar na 
dinâmica da matriz extracelufar, modificando a síntese de MMPs e TIMPs e 
inffuênciando a proliferação celular, quando ocorrem de forma controlada (ou 
desejável), são importantes para os processos fisiológicos como por exemplo 
para o reparo teciduaf. Já quando estas alterações ocorrem de forma 
descontrolada (ou indesejável) estão intimamente relacionadas a patogênese 
de doenças fibroprofiferativas, carcinogênese, invasões e metástases em 
diferentes tipos de cânceres, doenças autoimunes e doenças parasitárias 
(Ffanders and Roberts, 2000; Afberts et a/. 2002). 
A influência de TGF-jJ1 na proliferação de vários tipos celulares em 
processos fisiológicos e patológicos esta bem estabelecida na literatura. 
Artigos recentes relacionam a resposta pro/iterativa de fibrobfastos dermais a 
TGF-jJ1 em úlceras crônicas (La! BK et ai., 2003). TGF-fJ1 esta relacionado 
com a patogênese da doença de Dupuytren, uma doenca fibroprofiferativa 
afetando palmas e dedos das mãos, onde o efeito pro/iterativo e fibrogênico de 
TGF-jJ1 se apresenta exacerbado (Bayat A et ai., 2003). Na regulação do 
processo pro/iterativo de fibroblastos cardíacos, TGF-fJ1 induz a produção de 
CNP (C-type natriuretic peptide) um regulador autócrino que evita o excesso 
de fibrose cardiaca.(Horio T et a/.2003) Em pulmões de pacientes com fibrose 
pulmonar idiopática, abestosis crônica ou pneumonite, a expressão de TGF-(31 
se mostra bastante elevada, inicialmente este aumento na expressão é notado 
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em macrófagos alveolares e posteriormente também nas células epiteliais 
(Fianders and Roberts, 2000). Simmons et ai. mostraram que TGF-{31 estimula 
a proliferação de fibroblastos intestinais, além de estimular a síntese de 
colágeno tipo 1 nestas mesmas células (Simmons et ai. 2002). Em 
fibromatose gengiva/ hereditária, uma doença rara que afeta a cavidade oral e 
é caracterizada por um lento e progressivo aumento gengiva/, nós 
demostramos uma íntima relação de TGF-{31 com o maior potencial 
pro/iterativo de fibroblastos gengivais (Andrade et ai). Nossos resultados 
demonstraram que a neutralização de TGF-{31 significantemente reduz a 
proliferação celular de fibroblastos gengivais isolados de pacientes com esta 
doença, trazendo os índices de proliferação próximos aos níveis de fibroblastos 
gengivais normais. Recentemente, nós demonstramos que a adição de TGF-{31 
a fibroblastos gengivais humanos simultaneamente induz a expressão de 
colágeno tipo I e reduz os níveis de MMP-1 e MMP-2 (Marte/li-Junior et ai., 
2002). 
Tradicionalmente é inferida a produção local de matriz extracelular 
como causa do aumento gengiva/ em pacientes com fibromatose gengiva/ 
hereditária e hiperplasias gengivais induzidas por drogas. Contudo, recentes 
estudos demostram a importância dos mecanismos que regulam a proliferação 
celular e à síntese e degradação da matriz extracelular pelo acúmulo excessivo 
de tecido fibroso. A matriz extracelular é composta por várias famílias de 
proteínas, entre elas encontramos os co/ágenos, as lamininas, as tenascinas e 
os proteoglicanos. Além dessas quatro famílias serem compostas por proteínas 
grandes e de alta massa molecular, elas também apresentam domínios 
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est:"J: ':~is similares, favorecendo uma grande variedade de interações entre 
e' (Bosman and Stamenkovik, 2003). Apresentando uma estrutura 
:~mica, sua composição (em especial os colágenos), sendo regulada por 
ários fatores como a cinética celular, produção de citocinas e fatores de 
crescimento, atividade fagocitária, indução de apoptose, expressão de 
metaloproteinases de matriz (MMPs) e seus inibidores teciduais (TIMPs). De 
forma interessante, todos estes processos ja foram avaliados nos aumentos 
gengivais induzidos por drogas. Embora estes fatores sejam importantes na 
regulação da matriz extracelular, as MMPs parecem ser as principais enzimas 
relacionadas a dinâmica da matriz extracelular (Bosman and Stamenkovik, 
2003; Stamenkovik, 2003). 
As MMPs são endopeptidases dependentes de zinco, conhecidas pela sua 
capacidade de degradar várias macromoléculas da matriz extracelular. 
(Birkedai-Hansen 1993) Estas enzimas desempenham um papel fundamental 
em muitos processos fisiológicos como remodelamento tecidual durante o 
desenvolvimento, involução pós-parto, angiogênese, cicatrização e migração 
celular (Woessner, 1991). Na estrutura das MMPs é possível identificar um 
domínio de ativação e outro domínio do núcleo enzimático, o qual contém o 
sítio de ligação ao zinco (Birkedai-Hansen 1993). Todos os 23 membros da 
família MMP compartilham um razoável grau de homologia entre si. Apesar 
disto, existe uma especificidade de substratos. Por exemplo, apesar dos 50% 
de homologia entre colagenase de fibroblasto (MMP-1) e estromelisina (MMP-
3), ambas as enzimas apresentam substratos diferentes. Enquanto a 
estromelisina é capaz de degradar vários substratos incluindo proteoglicanos e 
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gelatina, a colagenase tem sua atividade dirigida primariamente contra 
moléculas de colágeno nativo (Harris et ai., 1984; Gross & Nagai, 1965). A 
especificidade das colagenases pelo co/ágeno nativo é surpreendente. Elas 
clivam ambas as cadeias da tripla hélice em um único ponto da molécula entre 
um resíduo de glicina e um de leucina ou isoleucina dependendo da cadeia alfa 
em questão (Harris et ai., 1984). A atividade catalítica das MMPs é regulada 
em múltiplos níveis, os quais incluem transcrição, secreção, ativação 
proteolitica da forma zimógeno e inibição da enzima ativa por inidores 
endógenos, entre estes os principais são os TIMPs. A expressão gênica das 
MMPs é regulada por uma variedade de agentes, incluindo a citocina TGF-/31. 
Em resposta a TGF-j31, fibroblastos reduzem a produção de MMP-1 e 2, 
enquanto elevam os níveis de expressão e produção de e TIMPs e colágeno 
(Overa/1 et. ai. 1989; Wahl et. ai. 1993). 
Visto que TGF-{31 regula muitos, se não todos, os eventos biológicos 
sugeridos estarem associados aos aumentos gengivais hereditários e induzidos 
por drogas (proliferação celular e desequilíbrio síntese/degradação da matriz 
extracelular}, o objetivo deste estudo é determinar o efeito da neutralização 
do estímulo autócrino de TGF-{31 na proliferação e expressão de MMPs e seus 
inibidores teciduais em fibroblastos gengivais normais tratados com CyA. 
l3 
2. OBJETIVO 
1. Determinar o efeito de cíclosporina A na expressão e produção 
de TGF-{31 em fibroblastos gengivais humanos. 
2. Analisar o efeito de Ciclosporina A na expressão e atividade 
enzimática de MMP-1 e 2 e TIMP-1 e 2 em fibroblastos 
gengivais. 
3. Verificar o efeito de Ciclosporina A e TGF-{31 na proliferação de 
fibroblastos gengivais. 
4. Analisar a influência da neutralização do estímulo autócríno de 
TGF-{31 na proliferação celular e na expressão de MMPs e TIMPs 
em fibroblastos gengivais humanos tratados com cíclosporina 
A. 
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3. CAPÍTULO 1. 
Expression of Matrix Metalloproteinases in Cyc/osporin -
Treated Gingival Fibroblasts is Regulated by Transforming Growth 
Factor (TGF) - [31 Autocrine Stimulation 
15 
asts Is 
~ !)1 t"acto 
P. Cotrim, * C. R. de Andrade,* H. Martelli-Junior, * E. Graner,* J.J. Sauk, t and R.D. Coletta* 
Background: Gingival overgrowth is a common side effect 
following the administration of cydosporin A (CsA). The patho-
genesis of this condition is not fully understood; however, recent 
studies show that CsA regulates the transcription of severa! 
cytokines including transforming growth factor-P1 (TGF-P1). 
The aim of this study was to investígate the potential role of 
TGF-P1 in the pathogenesis of CsA-induced gingival overgrowth, 
exploring a possible autocrine stimulation of TGF-P1 as a cel-
lular regulator of synthesis of matrix metalloproteinases (MMPs) 
and its tis sue inhibitors (TIMPs ). 
Methods: Gingival fibroblasts from human normal gingiva 
were incubated with increasing concentrations of CsA, cultured 
for 24 hours, and the expression and production of TGF-P1 
determined by semiquantitative reverse transcríptase-polymerase 
chain reaction (RT-PCR) and enzyme-linked ímmunosorbent 
assay (ELISA), respectively. MMPs and TIMPs mRNA expression 
leveis were also analyzed by RT-PCR. To determine the effect 
of TGF-P1 on the expression of MMPs and TIMPs by human gin-
gival fibroblasts under CsA treatrnent, human gingival fibroblasts 
cultures were treated with sense oligonudeotides (SON) or anti-
sense oligonudeotides (AON). 
Results: CsA simultaneously stimulated TGF-Pl expression 
and production and inhibited expression of MMP-1 and MMP-2 
by human gingival fibroblasts, whereas has a slight effect on 
TIMP-1 and TIMP-2 expression. AON reduced TGF-P1 produc-
tion as demonstrated by ELISA, whereas TGF-P1 mRNA ex-
pression leveis were not significantly modified. The inhibition of 
TGF-P1 production by AON modulated MMPs expression, dem-
onstrating the autocrine inhibitory effect of TGF-~1 in CsA-
treated human gingival fibroblasts. 
Conclusions: The data presented here suggest that TGF-~1 
in an autocrine fashion may contribute to a reduction of pro-
teolytic activity of human gingival fibroblasts in CsA-induced 
gingival overgrowth, which favors the accumulation of extra-
cellular matrix. J Periodonto/2002;73:1313-1322. 
KEYWORDS 
Cyclosporin A; transforming growth factor-~1; matrix 
metalloproteinases; gingival overgrowth. 
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C yclosporin A (CsA) is a hydropho-bic cyclic endecapeptide with un-surpassed immunosuppressive 
activity. 1 CsA is used for the treatment o f 
severa! diseases such as rheumatoid 
arthritis, psoriasis, nephrotic syndrome, 
and inflammatory bowel disease and to 
prevent organ rejection in transplanta-
tion. 2 Studies on the biological mecha-
nisms of CsA have shown that the drug-
cyclophilin complex binds and inhibits 
calcineurin, a calcium and calmodulin-
dependent serine threonine phosphatase. 
This inactivation prevents dephosphory-
lation of nuclear factor of activated T cells 
(NF-AT), the nuclear import of NF-AT, 
and the formation of a transcriptionally 
active NF-AT complex. The net conse-
quence, inhibition of interleukin-2 (IL-2) 
gene expression at the transcriptional 
levei, is considered to be the primary 
mechanism for the immunosuppressive 
activity of CsA. 3 The use of CsA is asso-
ciated with significant side effects, includ-
ing nephropathy, hypertension, hepato-
toxícity, thromboembolic complications, 
neurotoxicity, hypertricosis, and gingival 
overgrowth.4 ·9 Gingíval overgrowth is 
observed in 25% to 81% of the patíents 
undertaking CsA. 10 Such individual sus-
ceptibility to CsA-induced gingival over-
growth may be due to variations in drug 
responsiveness and tolerance. Clinically, 
gingival overgrowth is observed initially as 
a papillary enlargement, which is promi-
nent on the labial aspects and coalesces, 
resulting in a lobulated appearance. 11 
Despite extensive studies, the exact mechanism of 
induction of gingival overgrowth is unknown. Evidence 
obtained from both hurnan and animal models shows 
that CsA, in contrast to its inhibitory activity on IL-2 
gene transcription, stirnula tes the production o f the 
cytokine TGF-PL This potent CsA effect on TGF-P1 
transcription and secretion has been observed in vitro 
in human T lymphocytes, mouse proximal tubular cell 
!ines and tubulointerstitial fibroblasts, and in vivo in 
mouse and rat kidneys. 12-14 Recently, we demonstrated 
that CsA at similar concentrations found in the se rum 
of patients undergoing CsA treatment inhibits signifi-
cantly the production and activity of MMPs. 15 MMPs are 
zinc-dependent endopeptidases known for their ability 
to cleave severa! extracellular matrix molecules. 16 
Extensive evidence exists on the role of MMPs in medi-
ating normal and pathological processes, including 
embryogenesis, wound healing, inflammation, arthri-
tis, cancer, and fibrotic diseases. 17•23 The catalytic 
activity of the MMPs is regulated at multiple leveis 
including transcription, secretion, activation, and inhi-
bition. The latter is accomplished by members of the 
TIMP family (TIMP-1 to TIMP-4 ). MMPs and TIMPs gene 
expression is regulated by a variety of agents includ-
ing the TGF-P1 stimulation.24-26 Our previous results 
demonstrated that increased leveis of TGF-P1, in 
autocrine fashion, reduce the leveis of MMP-1 and 
MMP-2 affecting a state conducive to the net accu-
mulation of extracellular matrix in hereditary gingival 
fibromatosis. 27 The aim of the present study was to 
analyze the effect of CsA on expression and produc-
tion of TGF-P1, MMPs, and TIMPs by human gingival 
fibroblasts. Additionally, we assessed the role of 
autocrine stimulation by TGF-P1 on the MMPs and 
TIMPs expression of these cells using antisense oligonu-
cleotides directed against and overlapping lhe trans-
lation-start site of the TGF-Pl mRNA. 
MATERIALS ANO METHODS 
Cell Culture 
Human normal gingival fibroblast primary cultures 
were established using standard explant culture method 
as described previously. 28 Gingival samples from the 
attached gingiva were obtained by biopsies using 0.5 
mm punchs from 2 volunteers with clinically normal 
gingiva without evidence of inflammation, hyperpla-
sia, or history of taking drugs associated with gingival 
overgrowth. Cells were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM)f containing 10% fetal 
bovine serum (FBS), 100 Jlg/ml penicillin, 100 Jlg/rnl 
streptomycin, and 2 mM L-glutamine at 3TC in a 5% 
C02 air atmosphere. Ali experiments were performed 
using cells between the third and tenth passages. The 
study protocol was approved by the Ethical Commit-
tee in Research at the University of Campinas Dental 
School. 
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Treatment of Human Gingival Fibroblasts With CsA 
Human gingival fibroblasts grown to confluence in 25 
cm2 culture flasks§ in DMEM containing 10% FBS 
were washed with phosphate buffered saline (PBS), 
and cultured in serum-free DMEM containing O, 100, 
or 200 ng/ml of CsAil for 48 hours. Following serum 
starvation, the medium was replaced to fresh serum-
free DMEM containing the same concentrations of 
CsA and the cells incubated by an additional period 
of 24 hours. After treatrnent, the effects of CsA on 
TGF-P1 expression and production by human gingi-
val fibroblasts were analyzed using semiquantitative 
reverse transcriptase-polymerase chain reaction (RT-
PCR) and enzyme-linked immunosorbent assay 
(ELISA), respectively. The effect of CsA on MMPs and 
TIMPs expression was also analyzed. 
RNA Extraction and RT-PCR Analysis 
The expression of TGF-p1, MMP-1, MMP-2, TIMP-1, 
and TIMP-2 in human gingival fibroblasts after CsA 
treatrnent was assessed by RT-PCR. Total cellular RNA 
was isolated after the methods of Chomezynski and 
Sacchi29 using a reagent kit. f The concentration and 
purity of RNA in each sample was determined by spec-
trophotometry.~ Two micrograms of total RNA per sam· 
pie were used to generate cDNAs using H-reverse tran-
scriptase. i The resulting cDNAs were subsequently 
amplified in a 50 Jll reaction mixture containing 1 JlM 
of each primer,30•31 2 mM MgCI2 , 0.8 mM dNTPs, and 
0.25 U/Jll Taq DNA polymerase. P-actin was used as 
a housekeeping centro!. Primers for TGF-P1, MMPs, 
TIMPs, and P-actin are showed in Table 1. For TGF · 
P1 and P-actin amplifications, 34 cycles of amplifica-
tion were performed in a thermocycler, # followed by a 
final extension of 1 O minutes at 72°C. The cycling 
parameters were denaturation for 30 seconds at 94 oc, 
annealing for 1 minute at 55°C, and extension for 1 
minute at 72°C. For MMPs and TIMPs, 40 cycles of 
amplification were made with the following parame-
ters denaturation for 45 seconds at 93°C, annealing 
for 45 seconds at 58°C, and extension for 90 seconds 
at 72°C. After amplification, 2 Jll of each PCR product 
were electrophoresed on a 5% non-denaturing poly-
acrylamide gel and the PCR products silver stained as 
described by Sanguinetti et a!.32 The intensities of the 
PCR product bands were determined. * * Comparisons 
between different RT-PCR assays were ma de after nor-
malization of the TGF-Pl, MMPs, or TIMPs densito-
metric scans dividing each optical density value by P-
actin value. The resulting relative optical values were 
transformed in percentage of CsA stimulation in ratio 
to centro! and used for statistical analysis. 
T Gibco, BRL, Gaithersburg, MD. 
§ Nunc A/S, Roskilde, Denmark. 
11 Sandimmun-Sandoz, BraziL 
1 Genesys 2; Spectronic lnst., Rochester, NY. 
# Perkin Elmer, Foster City, CA. 
** Bio Rad Lab., Hercules, CA. 
Table I. 
Description of Primers Used in RT-PCR 
Primer Sequence 51 -v 3 r 
TGF-81 Sense MG TGG ATC CAC GAG CCC M 
Antisense GCT GCA CTT GCA GGA GCG CAC 
MMP-1 Sense GGT GAT GM GCA GCC CAG 
Anti-sense CAGTAG MT GGG AGA GTC 
MMP-2 Sense CCA CGT GAC MG CCC ATG GGG CCC C 
Anti-sense GCA GCCTAG CCA GTC GGA TTT GAT G 
Predicted size 
(base pairs) 
247 
438 
480 
to overlay to the cells for 24 
hours. After incubation, lhe effi-
ciency of lhe inhibition of TGF-
~1 was determined using RT-
PCR and ELISA. The role of 
autocrine stimulation of TGF-~1 
on expression of MMPs and 
TlMPs by CsA-treated human 
gingival fibroblasts was deter-
mined as described above. 
Statistical Analysis 
The data are expressed as per-
TI MP-I Sense TGC ACCTGT GTC CCA CCC CAC CCA CAG ACG 
Anti-sense GGCTAT CTG GGA CCG CAG GGA CTG CCA GGT 
551 centage of CsA stimulation in 
ratio to control (wilhout CsA) 
and represent lhe mean ± SEM 
of 2 cell !ines. Non-parametric TIMP-2 Sense CCG MTTCT GCA GCT GCT CCC CGGTGCACC CG 590 
Ant1-sense GGA AGCTTTTAT GGGTCCTCG ATG TCG AG one-way analysis of variance 
ELISA 
Sense TCA GM GGA CTC CTA TGT GG 
Anti-sense TCT CTTTGA TGT CAC GCA CG 
TGF-~1 in culture supernates of human gingival fibro-
blasts treated wilh different concentrations of CsA was 
quantified by ELISA. Before measurement, the super-
nates containing lhe Iatent form of TGF-~1 were con-
verted to an aclive form by treatment wilh 0.167 M HCI 
for 1 O minutes, followed by neutralization with 1 . 2 M 
NaOH in 0.5 M HEPES. The remaining cells were har-
vested using 0.2% trypsinrt and counted.H The sam-
ples were assayed using an ELISA kit§§ according to 
lhe manufacturer' s instructions. 
Neutralízatíon ofTGF-{Jl Translation Usíng 
Antisense Olígonucleotides 
Neutralization of TGF-~1 autocrine stimulation on CsA-
treated human gingival fibroblasts was performed as 
described by Le Roy et al.33 wilh some modificatíons. 
Fibroblasts grown to 70% confluence in 25 cm2 flask 
were incubated wilh serum-free DMEM containing 200 
ng/ml of CsA for 48 hours. The cells were transfected 
in serum free-DMEM with sense oligonucleotides 
(SON) or antisense oligonucleotides (AON) by a 
cationic liposome-mediated transfection melhod. Anti-
sense and sense 15-base deoxyribonucleotides corre-
sponding to lhe translation- initiation region of TGF-~ 1 
mRNA were: antisense 5' GGA GGG CGG CAT GGG 
3' and sense 5' CCC ATG CCG CCC TCC 3'. Briefly, 
oligonucleotides dissolved in one volume of DMEM 
wilhout FBS were mixed with lipofectAMINE reagent! 
dissolved in the same volume of medium and incu-
bated for 45 minutes at room temperature. Thereafter, 
the oligonucleotide-liposome complexes were diluted 
with 8 volumes of medium resulting in DMEM con-
taining 200 ng/ml of CsA, 1 flg/ml of each oligonu-
cleotides, and 1.25% of lipofectAMJNE, which was used 
506 (ANOVA) and multiple com-
parisons were used to test lhe 
treatments based on Kruskai-
Wallis test at 5% signifícance 
(P <0.05). Ali assays were performed at Ieast three 
times in independent experiments for each cell line. 
RESULTS 
Effect of CsA on the Expressíon and Production o f 
TGF-f31 by Human Gingival Fibroblasts 
Bolh RT-PCR and ELISA were used to verify whether 
CsA could affect TGF-~1 expression and production 
by human gingival fibroblasts. The semiquantitative 
RT-PCR assay was used in lhis study for lhe mea-
surement of steady state leveis of TGF-~1 mRNA. 
Total RNA was isolated from human gingival fibrob-
Iasts treated with O, 100, or 200 ng/ml of CsA for 24 
hours, and TGF -~ 1 mRNA and the constitutively 
expressed ~-actin mRNA (control for RT-PCR) were 
amplified using sequence-specific primers pairs (Fig. 
lA). The mRNA leveis were semiquantitated by den-
sitometric scanning and TGF-~1 mRNA expression 
was normalized to lhat of ~-actin mRNA display. For 
densitometric scans, ali bands of the ~-actin PCR 
products were used. RT-PCR studies revealed that 
CsA treatment results in an increased expression of 
TGF-~1 mRNA (Fig. lB; P <0.01). The TGF-~1 
expression in human gingival fibroblasts treated wilh 
100 and 200 ng/ml of CsA was elevated in 29.8 ± 
10.1% and 81.4 ± 40.5% (mean ±SEM of stimulation) 
of lhe value observed in corresponding normal con-
trol fibroblasts, respectively. To confirm lhese findings 
ELISA was performed revealing that normal cells 
treated with CsA dramatically elevated the TGF -~ 1 
production in 60- 120% of that observed in corre-
tt Sigma Chemical Co., St. Louls, MO. 
H Cou!ter Electronics, Luton, UK. 
§§R & D Systems, Mlnneapolis, MN. 
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A. Total RNA was isolated ond cDNA synthesízed by reverse 
transcriptase.After ampli(!cotJon using specíftc primers to TGF-8 I 
(pane//) and B-actin (pane! 11), the products were resolved in a 5% 
polyacry!amide gel and si/ver stained. Lanes are indicated as CsA 
concentrotion utilized 8. Comparison of TGF-B f mRNA expressíon in 
human gingiVal {lbroblasts (NG I ond NG3 fines) treated with CsA. CsA 
at 200 ng!ml significantfy stimulated the expression of TGF-B f. Values 
represem the means ± SEM from 3 independent experiments for 
each cellline andare expressed as the percentage of TGF-8 I 
stimulation normalized by B-actin *P <O. O I, 
sponding human gingival cell !ines without CsA treat-
ment (Fig. 2; P<0.001). TGF-~1 production was 62.1% 
higher in human gingival fibroblasts treated with 1 00 
ng/mi of CsA in comparison with centro! cells, whereas 
for human gingivai fibrobiasts treated with 200 ng/ml 
of CsA was 118.8% higher. 
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Figure 2. 
Effect ofCsA on production of TGF-BI by human gingiva/ (!broblasts. 
TGF-B I in culture supemates of CsA-treated human gingiva/ fibroblasts 
was activated by brief acidification fol!owed by capture ELISA Data 
are the mean ± SE/vl and represem 3 experiments in triplicate for 
each ce/1 fine. The amount of TGF-B I produced by human gingival 
fibrobfasts was significandy stimulated by CsA *P <0.00 I. 
E{fect of CsA on the Expression of MMPs and TIMPs 
by Human Gingival Fibroblasts 
We also determined whether CsA couid moduiate 
MMPs expression in the human gingivai fibrobiasts . 
Figure 3A (panels I and 11) depicts the expected ampli-
fication products of 438 and 480 base pairs that were 
detected in CsA-treated human gingivai cells with the 
MMP-1 and MMP-2 primers, respectiveiy. Normaliza-
tion for differences in mRNA loading revealed that the 
treatment of human gingival fibroblasts with CsA pro-
duced a significant reduction of MMP-1 and MMP-2 
expression in a dose dependent manner (Fig. 3B; P 
<0.01 ). The MMP-1 expression in human gingival 
fibrobiasts treated with 200 ng/ml of CsA was reduced 
to 65.3% of the vaiue observed in corresponding nor-
mal centrei fibrobiasts, whereas MMP-2 expression was 
reduced to approximately 49.3% of the value observed 
in centro! fibroblasts. Conversely, similar assays for 
TIMP expression revealed that TIMP-1 and TIMP-2 
mRNA leveis were increased after CsA treatment (Fig. 
3B, panels lll and IV). However, TIMP expression dif-
ferences were not statistically significant. 
E{fect o{ Antisense Oligonucleotides on Expression 
and Production o{TGF-P,l by Human Gíngíval 
Fíbroblasts 
Since CsA stimulates TGF-~1 expression and produc-
tion by human gingivai fibroblasts, we sought to deter-
mine if the excessive production of this cytokine by 
normal fibroblast, in an autocrine fashion, couid medi-
ate lhe proteolytic activities of those cells. In an attempt 
to block endogenous TGF-~1. human gingival fibro-
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Expression o( MMP-1, MMP-2, TIMP-1 and TIMP-2 in human gingiva/ 
frbroblasts treated with CsA A. Total RNA isolated (rom gingival 
ftbrobiasts after CsA treatment were subjected to RT-PCR assays using 
specifrc primers (or MMP-1 (panellj, MMP-2 (pane!//), T/MP-1 (pane! 
///), and T!MP-2 (pane/ IV). Pane/ V represents 6-actin housekeeping 
reoction Lones are indicated as CsA concentratíon ut!'Jized. 
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medium reduced MMP-1 mRNA approximateiy to 65% ond MMP-2 mRNA to 47'/o ofthe va/ue observed in correspondíng normal centro/ (!brob!asts. 
T/MP-1 and T!MP-2 mRNA leveis after CsA treatment were slightly greater ar equivafent than those in centro! cel!s. Values are expressed os 
percentage o f stimulation mean to specif!c mRNA leveis ± SE!vl o f 3 independent experiments for each ce/f line. Densitometric reading were 
normolized to equivalent amounts o f B-actin housekeeping mRNA. *P <0.0!. 
blasts were transfected with 1 !J.g/ml of AON comple-
mentary to the translation initiation region of human 
TGF-~1 mRNA. As a control, a corresponding SON 
was used. The results showed (Fig. 4) that neither 
AON nor SON modified the leveis of TGF-~1 mRNA. 
In contrast, the investigation of amount of TGF -131 
secreted in culture supernates by CsA-treated normal 
cells by ELISA revealed that AON significantly reduced 
TGF-131 production in approximately 65% (65.8 ± 
25.38%) in comparison with SON. Similar results were 
obtained by Le Roy et ai.33 using fibroblast-like cells 
isolated from interstitial tissue from testis and by 
Andrade et al.34 using gingival fibroblasts. In so doing, 
these studies revealed the efficacy of AON on the neu-
tralization of TGF-~1 production without modify TGF-
~1 mRNA leveis. 
1<17 
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Figure 4. 
Representa tive RT-PCR assay of effect of sense oligonudeotides (SON) 
and antisense oligonuc/eotJdes (AON) on TGF-81 mRNA expression by 
human gingival ftbroblasts. Pane! I represents speci{!c ampli(!cation 
reaction for TGF-B I and pane! I! for 8-actin. Neither AON nor SON 
modi{ied signi{icantJy the leveis of TGF-61 transcripts. 
Effect of Antisense Oligonucleotides on MMPs and 
TIMPs Expression by Human Gingival Fibroblasts 
Since CsA treatment elevated the expression and pro-
duction ofTGF-~1 and simultaneously inhibited MMPs 
expression, we examined whether elevate leveis of 
TGF-~1 protein induced by CsA correlates with MMPs 
and its tissue inhibitors mRNA leveis. The results clearly 
show that the treatment with AON partially abrogated 
the effects of 200 ng/ml of CsA on expression of MMP-
1 and MMP-2 by human gingival fibroblasts in com-
parison with the treatment with SON. Results show 
(Fig. 5) that AON increased significantly the MMP-2 
expression to CsA treatment about 50% compared to 
SON (P<0.05). The effect of CsA on MMP-1 expres-
sion was partially reverted by AON, but not at signif-
icant leveis (P= 0.15). The expression ofTIMP-1 and 
TIMP-2 was unaffected with AON or SON treatment. 
To further test the specificity of the AON, we exam-
ined whether exogenous TGF-~1 could reverse the 
effects of antisense treatment. We demonstrated that 
10 ng/ml of TGF-~1 completely reversed the effects 
of the AON on MMP-1 and MMP-2 expression by CsA-
treated human fibroblast cells (Fig. 6). 
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DISCUSSION 
A number of histological and biochemical studies have 
investigated the changes in tissue composition and 
cellular function that accompanies CsA-induced gin-
gival overgrowth. It has been demonstrated that CsA 
affects gingival fibroblast proliferation,35 prometes 
abnormal synthesis of collagen and other extracellu-
lar matrix moiecules,36 decreases collagen turnover 
by inhibiting collagen phagocytosis and collagen 
degradíng enzymes,37·38 and also appears to act on 
abnormal cytokines production39.4° Although the exact 
mechanísm by which CsA induces gingíval overgrowth 
remains unclear, our understanding of the biochemi-
cal mechanisms involved in producing these tissue 
alterations is evolving. For example, increased TGF-
~1 production has recently been demonstrated in CsA-
induced gingival overgrowth41 as well as in other 
fibrotic side effects of CsA-treatment.42,43 
TGF -~ 1 is a multifunctional peptide that regulates 
diverse biologic activities including cell growth, cell 
death or apoptosis, cell differentiation, and extracellular 
matrix synthesis.44 TGF-~1 is believed to be a key 
mediator of tissue fibrosis as a consequence of extra-
cellular matrix accumulation in pathologic states such 
as hereditary gingival fibromatosis27 and progressive 
renal diseases including CsA-induced nephropathy.45 
TGF-~1 actions are mediated by the heteromeric inter-
actions of types I and 11 serine/threonine kinase recep-
tors. lnitiation of signaling requires binding of TGF-~1 
to TGF -~ type 11 receptor, a constitutively active ser-
ine/threonine kinase, which subsequently transphos-
phorylates TGF-~ type I receptor. F ollowing the initial 
receptor interaction with ligand, evidence suggests the 
transcriptional activation of mitogen-activated protein 
kinase (MAPK) and CTF-1, the prototypic member of 
the CTF /NF-1 family of transcription factors. This induc-
tion correlates with the proposed role of CTF/NF-1 
binding sites in collagen and MMP gene inductions by 
TGF-~. However, the exact mechanism of TGF-~ sig-
nal transduction remains poorly understood. 46 
Our previous study showed that CsA significantly 
inhibits the production and activity of MMP-1, MMP-2 
and MMP-3 at the same concentrations found in the 
serum of patients undertaken CsA-treatment. 15 Since 
TGF -~ 1 expression is stimulated by CsA and its effect 
can modulate MMPs and TIMPs production as well as 
stimulate fibroblasts proliferation and collagen syn-
thesis, we were interested in determining whether 
human gingival fibroblasts after CsA treatment alter 
TGF-~1 expression and production. To the best of our 
knowledge, no previous investigation has analyzed the 
direct effect of CsA on TGF-~1 expression and pro-
duction by normal gingival fibroblasts. In this study 
we have determined that CsA simultaneously upreg-
ulates the expression and production o f TGF -~ 1 and 
downregulates MMP expressíon from human gingival 
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fibroblasts. Furthermore, blocking TGF-~1 synthesis 
wilh AON resulted in an increased effect of CsA on 
the MMP-1 and MMP-2 expression by gingival fibro-
blasts, whereas TlMP-1 and TlMP-2 were unaffected. 
Additionally, our data also revealed that lhe TGF-~1 
signaling palhways are not compromised by lhe treat-
ment with oligonucleotides, since exogenous TGF-~1 
reversed the effects of the AON. 
The collagen turnover in gingival tissues promoted 
by fibroblasts occurs by 2 systems: lhe phagocytic 
pathway and lhe MMP-dependent palhway. 18.47 CsA 
may alter bolh pathways, reducing phagocytosis or 
inhibiting lhe secretion of MMPs by gingival fibroblasts. 
The role of MMP-1 in interstitial collagen degradation 
is well documented. On lhe other hand, MMP-2 inhi-
bition may contribute to an abnormal accumulation of 
glycosaminoglycans and proteoglycans, substrates for 
MMP-2, in the CsA-treated gingival tissue. Conse-
quently, the scenario in which a net reduction in de-
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Figure 5. 
Effect of sense oligonuc/eotides (SON) and ant.isense o!igonudeotides 
(AON) on MMP-1, MMP-2, T/MP-1, ond TIMP-2 expression by CsA-
treoted human gingíval fibrob!asts. A. Total RNA was isolated from 
humon gingival {ibroblasts treated with 200 nglml of CsA and with 
200 nglml ofCsA plus SON or AON.Aft-er reverse tronscriptase, cDNA 
was ampli(ted for MMP-1 (pane//), MMP-2 (pane///), T/MP-1 (pane/ 
111), T/MP-2 (pane! IV), and B~actin (pane/ V). B. Densitometric analysis 
showing thatAON reversed significant!y CsA effect on MMP-2 mRNA 
expressíon leveis. Va/ues are expressed as optica/ density units 
normalized by f3-actin and represent the mean ± SEM of 3 
independent assays for 2 ce/1/ines. *P <0.05. 
gradative activity exists in CsA-treated normal gingi-
val cells may contribute to lhe increased collagen con-
tent even in the absence of increased collagen gene 
expression. Recently, Arora et ai.38 have demonstrated 
lhat CsA inhibits fibroblast collagen phagocytosis by 
blocking calcium release from endoplasmatic reticu-
lum. Since TGF -~ 1 induces calei um release from endo-
plasmatic reticulum and mitochondria, stimulating 
severa! cellular effects as cell prolíferation, 48.49 lhe de-
crease on fibroblasts phagocytosis under CsA treat-
ment may be dueto TGF-P1 overexpression. 
The studies presented here also revealed that TIMP 
leveis after CsA treatment were slightly greater than 
those in control cells and remained unaltered follow-
ing neutralization with TGF-~1 antisense oligonu-
cleotides. Allhough lhe effect of CsA on TIMP expres-
sion leveis was not statistically significant, the 
stimulation of TlMP-1 was stronger than of TlMP-2. 
The effects of CsA on TIMP-1 expression by human 
fibroblasts strains display both inter-individual and 
intra-individual heterogeneity, 50 and in human dermal 
fibroblast cultures CsA does not affect TIMP-1 expres-
sion.51 On the other hand, CsA-induced focal intersti-
tial fibrosis is associated with locally increased expres-
sion of TMP-1 rather than a decrease of MMP 
expression. 52 lnterestingly, TlMPs expression pattern 
is the same in hereditary gingival fibromatosis fibro-
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blasts and in gingival fibroblasts after CsA treatment. 27 
The reciproca! findings of MMPs and TIMPs in heredi-
tary gingival fibromatosis compared to CsA-induced 
gíngival overgrowth would suggest that different pop-
ulations of gingival cells are affected, o r that the TGF-
~1 is not the only pathway involved. Analogously, alter-
ations in the MMPs and TIMPs expression have been 
implicated in a variety of other diseases that include 
fibrosis as a component.53·55 Collectively, these stud-
ies índicate that dysregulation of the proteolytic equi-
Iibrium is a common basis for pathological fibrosis in 
various organ systems including the gingiva of patients 
with hereditary gíngíval fibromatosis as well as in CsA-
induced gíngival overgrowth. 
In summary, our investigation of the molecular 
events that lead to CsA-índuced gingival overgrowth 
shows a stimulation of TGF-~1 expression and pro-
duction and dowregulation of MMP-1 and MMP-2 
mRNA leveis. Additionaly, these effects seem to be 
mediated by TGF-~1 in an autocrine fashion. Thus a 
CsA-induced alteration in the TGF-~1 profile within 
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Figure 6. 
Reversion of effect of antJsense oligonuc!eotides (AON) on MlvlP-1 and 
MMP-2 expression by addition of exogenous TGF-61. Human gingival 
(tbroblasts were cultured for 24 hours in presence of 200 nglml of 
CsA, I pg/ml of AON, ond I O nglmi ofTGF-B I, RTPCR (A) and 
densitometric analysis (B). Pane! I represents MMP-1, pane!// 
represents MMP-2, and pane/li/ represent B-actin The reversion 
showed that TGF-13 f pathway is independent of treatment with AON. 
gingival tissues may underlie the clinicai changes which 
present as gingival overgrowth. 
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Background: Cyclosporin A (CyA) is a widely used immunosuppressant which 
causes significant side effects including gingival overgrowth. The pathogenesis of 
this condition is not fully understood; however, recent studies show that CyA 
regulates the transcription of severa! cytokines including transforming growth 
factor-beta1 (TGF-(31 ). In this work we evaluated the effects of CyA and TGF-(31 on 
human normal gingival (NG) fibroblast proliferation, and explored a possible 
autocrine stimulation of TGF-(31 as a cellular regulator of proliferation induced by 
CyA in NG fibroblasts. 
Methods: NG fibroblast cell lines were incubated with increasing concentrations 
of CyA or TGF-(31 and the proliferation index determined by automatic cell 
counting, BrdU incorporation, PCNA expression and mitotic potential. To determine 
the effect of TGF-(31 on the proliferation rate of NG fibroblasts under CyA 
treatment, NG fibroblast cultures were simultaneously treated with CyA and 
antisense oligonucleotides against the translation-start site of the TGF-(31 mRNA. 
Results: Treatment of NG fibroblasts with CyA or TGF-(31 stimulated significantly 
the cell proliferation in a dose-dependent manner. Furthermore, neutralization of 
TGF-(31 production in CyA-treated NG fibroblast inhibited CyA effect on the NG 
fibroblasts proliferation, demonstrating an autocrine stimulatory effect of TGF-(31 in 
CyA-treated NG fibroblast proliferation. 
Conclusion: The results presented here suggest that CyA stimulatory induction 
of NG fibroblast proliferation is mediated through of TGF-(31 in an autocrine 
fashion. 
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Cyclosporin A (CyA) is a cyclic undecapeptide with highly specific 
immunosuppressive effects that is commonly used in the treatment of allograft 
rejection.1 Previous immunological studies have revealed that CyA blocked calcium 
and antigen-dependent proliferation of T lymphocytes by inhibiting specific nuclear 
transcription factors that regulate expression of cytokine genes such as interleukin-
2.2 Formation of complexes between CyA and cyclophilin A blocks the calcium-
activated phosphatase activity of calcineurin resulting in the inhibition of the 
translocation of nuclear factor of activated T-cell dephosphorylation into the 
nucleus, thus leading to the lack of interleukin-2 expression.3 The use of CyA is 
associated with significant side effects, including nephropathy, hypertension, 
hepatotoxicity, thromboembolic complications, neurotoxicity, hypertricosis and 
gingival overgrowth.4-9 
In spite of extensive studies, the exact mechanism by which CyA induces 
gingival overgrowth is unknown. Evidence obtained from both human and animal 
models shows that CyA, in contrast to its inhibitory activity on interleukin-2 gene 
transcription, stimulates the production of the cytokine transforming growth factor-
beta1 (TGF-f31 ). This potent CyA effect on TGF-f31 expression and production has 
been observed in vitro in T lymphocytes, mouse proximal tubular cell lines and 
tubulointerstitial fibroblasts, and in vivo in mouse and rat kidneys.10-12 Recently, we 
demonstrated that concentrations of CyA that are similar to those found in the 
serum of immunossupressed patients stimulate significantly the expression and 
production of TGF-f31 by normal gingival (NG) fibroblasts. 13 TGF-f31 is a cytokine 
produced by different cell types which acts on various cells including lymphocytes, 
29 
macrophages, hepatocytes as well as keratinocytes and fibroblasts.14 Among its 
pleiotropic effects, TGF-~1 stimulates cell growth, cell death or apoptosis, cell 
differentiation and extracellular matrix synthesis.15 TGF-~1 is believed to mediate 
tissue fibrosis as a consequence of stimulation of cell proliferation and of 
extracellular matrix accumulation in pathologic states such as hereditary gingival 
fibromatosis 16·17 and progressive renal diseases including CyA-induced 
nephropathy.18 Fibroblast proliferation can be upregulated by a variety of agents 
including the cytokine TGF-~1. 19-21 The aim of the present study was to analyze the 
effects of CyA and TGF-~1 on the proliferation of NG fibroblasts. Additionally, we 
assessed the role of autocrine stimulation of TGF-~1, which is produced in higher 
amounts by CyA-treated NG fibroblasts,13 on the proliferation rates of these cells 
using antisense oligonucleotides directed against and overlapping with the 
translation-start site of the TGF-~1 mRNA. 
Material and Methods 
Cell culture 
Human NG fibroblast primary cultures were established using standard explant 
cultura method as described previously.22 Gingival samples were obtained from the 
attached gingiva of one Caucasian male and one Caucasian female, with age of 26 
and 29 years old respectively. The gingivas were clinically normal without 
evidences of inflammation or hyperplasia. Cells were cultured in Dulbecco modified 
Eagle's medium· (DMEM) containing 10% fetal bovine serum (FBS), 100 J.I.Q/ml 
• Gibco, BRL, Gaithersburg, MD. 
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penicillin, 100 f.lg/ml streptomycin, and 2 mM L-glutamine at 37°C in a 5% C02 air 
atmosphere. Ali experiments were performed using cells between the third and 
tenth passages. The study protocol was approved by the Ethical Committee in 
Research at the University of Campinas Dental School. 
Effect of CyA and TGF-131 treatment on cell proliferation 
Fibroblasts from NG were plated in triplicate in 24-well cultura plates ata density of 
30,000 cells/well in DMEM containing 10% FBS and antibiotics. After 16 h, the 
cells were rinsed with phosphate buffered saline (PBS), and the medium replaced 
with serum-free DMEM for an additional 24 h. Following serum starvation cells 
were stimulated with 2% charcoal-treated (CT)-FBS/DMEM supplemented by 
either O, 50, 100, 200, 400 and 800 ng/ml of CyAt or by O, 0.001, 0.01, 0.1, 1 and 
10 ng/ml of TGF-J31.* Cells were harvested after 24 h using 0.2% trypsin in PBS 
and counted with a Coulter Counter.§ 
Bromodeoxyuridine-labeling (BrdU) index 
NG fibroblasts were plated in 8-well chamber slides •• at a density of 30,000 cells 
per well, in 500 f.LI of DMEM containing 10% FBS. After 16 h, the cells were 
washed with PBS and cultured in serum-free DMEM for an additional 24 h. 
Following serum starvation, the medium was replaced by 2% CT-FBS/DMEM 
containing either 100 and 200 ng/ml of CyA or 0.1 and 1 ng/ml of TGF-J31. 
t Sandimmun-Sandoz, Sao Paulo, Brazil. 
! R&D Systems, Minneapolis, MN. 
§ Coulter Electronics, Luton, England. 
•• Nunc NS, Roskilde, Denmark. 
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Proliferation rates were determined 24 h after treatment by measuring BrdU 
incorporation into DNA. Briefly, BrdU antigen ata dilution of 1:1,000 was added to 
the culturas and kept for 1 h at 37°C in 5% C02. After incubation, cells were 
washed in PBS and fixed in 70% ethanol for 1 h. BrdU incorporation in proliferating 
cells was measured using an immunohistochemical analysis kit.tt The BrdU-
labeling index, expressed as the percentage of cells labeled with BrdU, was 
determined by counting 1 ,000 cells in three independent reactions for each 
concentration using an image analysis system.:)::l: 
Proliferating cell nuclear antigen (PCNA) index 
Cell suspensions (30,000 cells) were cultured in culture chamber slides at 37°C in 
humidified ai r containing 5% C02 for 24 h. After incubation with CyA o r TGF-~ 1 for 
24 h as described above, the cells were fixed in 70% ethanol for 1 h and washed 
with PBS. Cells were then treated with 1% bovine serum albumin§§ (BSA) diluted in 
PBS for 1 h, incubated with monoclonal antibodies against PCNA ... (clone PC-10 
diluted 1 :3,000), and followed by the ABC method (StrepABC Complex/HRP). 
Reactions were developed with 0.6 mg/ml 3,3'-diaminobenzidine tetrahydrochloride 
(OAB) containing 0.01% H202. The PCNA index was calculated using an image 
analysis system by counting labeled nuclei of 1 ,000 cells in three independent 
reactions, and was expressed as percentage of PCNA positive cells. 
tt Amershan Pharmacia Biotech Inc., Piscataway, NJ. 
H KONTRON 400, Zeiss, Eching bei Munich, Germany. 
§§Sigma Chemical Co., St. Louis, MO. 
*** Dako Corp., Carpenteria, CA. 
32 
Mitotic index 
NG fibroblasts were plated in glass chamber si ides and treated with 100 and 200 
ng/ml of CyA or 0.1 and 1 ng/ml of TGF-f31. After 24 h, the cells were fixed in 70% 
ethanol and then stained with hematoxylin and eosin (H&E). Thirty randomly 
selected microscopic fields of 0.0256 mm2 (approximately 1,000 cells) were 
examined for each fibroblast cell line and the number of cells in mitosis 
determined. Mitotic index was expressed as the percentage of cells in mitosis per 
field ± SD. 
Neutralization of TGF-f31 translation using antisense oligonucleotides 
Neutralization of TGF-f31 autocrine stimulation on CyA-treated NG fibroblasts was 
performed as described by Le Roy et al.23 with some modifications. Fibroblasts 
grown to 70%-confluence in 25-cm2 flasks were incubated with serum-free DMEM 
containing 200 ng/ml of CyA for 48 h. The cells were transfected in serum free-
DMEM with sense or antisense oligonucleotides by a cationic liposome-mediated 
transfection method. Antisense and sense 15-base deoxyribonucleotides 
corresponding to the translation-initiation region of TGF-f31 mRNA were: antisense 
5' GGA GGG CGG CAT GGG 3' and sense 5' CCC ATG CCG CCC TCC 3'. 
Briefly, oligonucleotides dissolved in one volume of DMEM without FBS were 
mixed with lipofectAMINE reagent* dissolved in the same volume of medium and 
incubated for 45 min at room temperature. Thereafter, the oligonucleotide-liposome 
complexes were diluted with 8 volumes of medium resulting in DMEM containing 
200 ng/ml of CyA, 1 Jlg/ml of each oligonucleotides and 1.25% of lipofectAMINE, 
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which was used to treat the cells for 24 h. After incubation, the efficiency of the 
inhibition of TGF-~1 was determined using enzyme-linked immunosorbent assay 
(ELISA) and semiquantitative reverse transcriptase-polymerase chain reaction 
(RT-PCR). The role of autocrine stimulation of TGF-~1 on proliferation rate of CyA-
treated NG fibroblasts was assessed by automatic counting as described above. 
ELISA 
After oligonucleotide treatments, the conditioned cell culture medium was used to 
quantify TGF-~1 production by CyA-treated NG cells, and the cells were incubated 
in guanidine thiocyanate for total cellular RNA extraction (see below). Before 
measurement, the latent form of TGF-~1 in the conditioned cell culture medium 
was converted into the active form, by treatment with 0.167 M HCI for 10 min, 
followed by neutralization with 1.2 M NaOH in 0.5 M HEPES. The samples were 
assayed using an ELISA kit~ according to the manufacturer's instructions. The 
values were expressed as percentage of inhibition of TGF-~ 1. 
RNA extraction and RT -PCR analysis 
The expression of TGF-~1 in CyA-treated NG fibroblasts after each oligonucleotide 
treatment was assessed by RT-PCR. Total cellular RNAs were isolated after the 
methods of Chomezynski and Sacchi24 using the Trizol™ reagent kit. • The 
concentration and purity of RNA in each sample was determined by the absorption 
at 260/280 nm using a spectrophotometer.ttt Two micrograms of total RNA per 
ttt Genesys 2, Spectronic lnst., Rochester, NY. 
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sample were used to generate cDNAs using Superscript 11 RNase H-reverse 
transcriptase. * The resulting cDNAs were subsequently amplified in a 50 f.!l 
reaction mixture containing 1 f.!M of each primer,25 2 mM MgCb, 0.8 mM dNTPs 
and 0.025 U/!!1 Taq DNA polymerase.* !3-actin was used as a housekeeping 
control. Primers used to amplify TGF-!31 were 5' AAG TGG ATC CAC GAG CCC 
AA 3' (sense) and 5' GCT GCA CTT GCA GGA GCG CAC 3' (antisense). For !3-
actin, primers used were 5' TCA GAA GGA CTC CTA TGT GG 3' (sense) and 5' 
TCT CTT TGA TGT CAC GCA CG 3' (antisense). After denaturation for 3 min at 
93°C, 34 cycles of amplification were performed using a model 9700 
thermocycler,m followed by final extension of 10 min at 72°C. The cycling 
parameters were: denaturation for 30 s at 94°C, annealing for 1 min at 55°C, 
extension for 1 min at 72°C. After amplification, 2 f.!l of PCR product were 
electrophoresed on a 5% non-denaturing polyacrylamide gel and the PCR products 
stained with silver as described by Sanguinetti et al.26 
Statistical analysis 
The data represent the mean ± SD of 2 cell lines. One-way analysis of variance 
(ANOVA) and multiple comparison were used to test group effects and treatments 
based on Newman-Keuls test at 5% significance (P<0.05). Ali assays were 
performed at least three times in triplicate or in quadruplicate. 
m Perkin Elmer, Foste r City, CA. 
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Results 
Effect of CyA on NG cell proliferation 
The effect of CyA on the proliferation of NG fibroblasts was initially assessed by 
automatic counting of cell number. The effect of increasing concentrations of CyA 
on proliferation of NG fibroblasts is depicted in Fig. 1. CyA at 50-200 ng/ml 
increased NG proliferation with the maximal stimulation being observed at 
concentration of 200 ng/ml (p<0.05). With increasing concentrations of CyA (400 
and 800 ng/ml), NG fibroblast proliferation was inhibited. Our data in conjunction 
with previous studies27 that demonstrated a serum levei of CyA range between 
100-250 ng/ml in patients undergoing CyA-treatment, let us perform ali subsequent 
studies with CyA concentrations of 1 00 and 200 ng/ml. 
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Fig. 1. Effect of CyA on NG fibroblast proliferation. NG fibroblasts were exposed 
for 24 h to increasing concentrations of CyA, harvested with 0.2% trypsin, and 
counted with an automated cell counter. Each concentration-point represents the 
mean of 16 counts for each cell line and is expressed as the mean ± SD of 2 
fibroblast celllines. *p<0.05 
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Our cell growth assays indicated that CyA has a direct effect on the 
proliferation of NG fibroblasts. To confirm these results, proliferation indexes of NG 
fibroblasts cultured for 24 h with 1 00 or 200 ng/ml of CyA were assessed by 
measuring BrdU incorporation into DNA, PCNA expression, and determination of 
mitotic potential of the cells. Nuclear immunoreactivity for BrdU and PCNA were 
clearly and easily identified. Nuclei with a clear brawn calor, regardless of the 
intensity of staining, were interpreted as positive. Fig. 2A shows that CyA at 200 
ng/ml significantly increased the BrdU-Iabeling index of NG fibrablasts (p<0.001 ). 
NG fibroblasts treated with 100 and 200 ng/ml of CyA enhanced BrdU-Iabeling 
index by approximately 52.3% and 96.5% respectively, in comparison with the 
contrais without CyA. PCNA leveis in NG fibroblasts that were incubated with 200 
ng/ml of CyA were also significantly higher than those of contrai (Fig. 28; p<0.01). 
In the presence of 100 and 200 ng/ml of CyA, NG fibroblast PCNA indexes were 
stimulated by approximately 15.4% and 61.4%, respectively, compared to the 
contrais. Mitotic activity measured by direct counting showed significantly higher 
percentage of cells in mitosis in NG cells treated with 200 ng/ml compared to the 
contrais (Fig. 2C; p<0.05). 
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Fig. 2. BrdU-Iabeling (A), PCNA (B) and mitotic (C) indexes of NG fibroblasts 
incubated with 100 and 200 ng/ml of CyA for 24 h. The data of BrdU-Iabeling, 
PCNA and mitotic indexes correspond to the mean percentage of positive cells of 2 
fibroblast cell lines. Addition of 200 ng/ml of CyA significantly stimulates the 
proliferation rate of NG fibroblasts. *p<0.05 
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Effect of TGF-P1 on NG cell proliferation 
A 24 h incubation with TGF-~1 produced a significant increase in the proliferative 
rate of NG fibroblasts relative to controls (without TGF-131). A significant increase in 
cell proliferation was observed at a TGF-131 concentration of 0.1 and 1 ng/ml 
(p<0.05). However, at 10 ng/ml, TGF-~1 decreased NG cell proliferation (Fig. 3). 
No significant difference in the relative proliferative rate between 0.1 and 1 ng/ml of 
TGF-131 was observed. The effect of TGF-131 on NG fibroblast proliferation was 
also determined using BrdU-Iabeling, PCNA and mitotic indexes. The data of these 
three different cellular proliferation assays are depicted in Fig. 4 (A, B and C). The 
BrdU-Iabeling, PCNA and mitotic indexes of NG fibroblasts treated with 1 ng/ml of 
TGF-131 were significantly higher than those of controls (p<0.01 for BrdU-Iabeling 
and mitotic indexes and p<0.05 for PCNA index). BrdU-Iabeling and mitotic 
indexes of NG fibroblasts incubated with 0.1 ng/ml of TGF-131 were also 
significantly higher than those of controls (p<0.05), but not different from those 
treated with 1 ng/ml of TGF-131. 
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Figure 3. 
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Fig. 3. Effect of TGF-P1 on NG fibroblast proliferation. Serum-starved cells were 
cultured in presence of various concentrations of TGF-P1 for 24 h. The combined 
results from 4 experiments for each cell line are presented as the number of cells ± 
SD. *p<O.OS 
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Fig. 4. Proliferation analysis of NG fibroblasts after addition of TGF-P 1. NG 
fibroblasts were grown for 24 h in presence of 0.1 o r 1 ng/ml TGF-P 1. Following 
treatment, BrdU-Iabeling (A), PCNA (B) and mitotic (C) indexes were determined. 
The BrdU-Iabeling, PCNA and mitotic indexes of NG fibroblasts treated with 1 
ng/ml of TGF-P1 were significantly higher than those of control. BrdU-Iabeling and 
mitotic indexes of NG fibroblasts incubated with 0.1 ng/ml of TGF-P1 were also 
significantly higher than those of control. *p<O.OS; **p<0.01 
42 
Effect of antisense oligonucleotides on expression and production of TGF-131 
by NG fibroblasts 
Since TGF-131 stimulates NG fibroblast proliferation, we sought to determine if the 
excessive production of this cytokine by CyA-treated NG cells, in an autocrine 
fashion, could mediate the proliferative behavior of those cells. In an attempt to 
block endogenous TGF-131 , NG fi broblasts were transfected with 1 ~-tQ/ml of 
antisense oligonucleotides complementary to the translation initiation region of 
human TGF-131 mRNA. As a contrai, corresponding sense oligonucleotide was 
used. To determine the efficacy of antisense oligonucleotides on the neutralization 
of TGF-131 production, we investigated the amount of TGF-131 secreted in culture 
supernatants by NG cells lines by ELISA. These studies revealed that antisense 
oligonucleotides significantly reduced TGF-131 production by approximately 65% 
(65.8 ± 25.38%) in comparison with sense oligonucleotides. Similar results were 
obtained by Le Roy et al.23 using fibroblast-like cells isolated from interstitial tissue 
from testis and by Andrade et al.17 using gingival fibroblasts. To confirm that TGF-
131 antisense oligonucleotides promoted a translation arrest of TGF-131 mRNA, we 
studied the TGF-131 mRNA leveis by RT-PCR. Neither antisense nor sense 
oligonucleotides modified significantly the leveis of TGF-131 transcripts (data not 
shown). 
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Effect of antisense oligonucleotides NG cell proliferation 
To determine whether CyA regulates NG cell proliferation by TGF-~ autocrine 
stimulation, antisense oligonucleotides were used to block TGF-~1 production by 
CyA-treated NG fibroblasts. Cell proliferation was then assessed by cell number 
counting as shown in Fig. 5. These results clearly show that the treatment with 
antisense oligonucleotides abrogated the effects of 200 ng/ml of CyA on 
proliferation of NG fibroblasts in comparison with the treatment with sense 
oligonucleotides (p<0.05). To further test the specificity of the antisense 
oligonucleotides, we examined whether exogenous TGF-~1 could reverse the 
effects of antisense treatment. We demonstrated that TGF-~1 at concentrations of 
0.1 ng/ml or greater reversed significantly the effects of the antisense 
oligonucleotides on NG cell proliferation (Fig. 5 and data not shown; p<0.01). 
These data suggest that CyA upregulates cell proliferation in human NG fibroblasts 
via a TGF-~1-dependent mechanism. Furthermore, these results indicate that the 
TGF-~1 signaling pathways are not compromised by the treatment with antisense 
oligonucleotides. 
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Fig. 5. Effect of antisense oligonucleotides on CyA-treated NG cell proliferation. 
NG fibroblasts were cultured in 24-well plates in DMEM with 10% FBS for 16 h and 
replaced with serum-free medium. After 24 h, 200 ng/ml of CyA in association with 
1 J.tQ/ml of antisense oligonucleotides (AON) or sense oligonucleotides (SON) were 
administered. To further test the specificity of the antisense oligonucleotide effect, 
NG fibroblasts were cultured in presence the both 1 J.tQ/ml of antisense 
oligonucleotides and 0.1 ng/ml of TGF-~1. Following treatment, proliferation rates 
were determined by automated cell counting. The proliferation rate of NG 
fibroblasts treated with antisense oligonucleotides was significantly lower than that 
cells those treated with sense oligonucleotides. The reversal of inhibition after 
addition of exogenous TGF-~1 showed that this pathway is independent of 
treatment with antisense oligonucleotides. *p<0.05; **p<0.01 
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Discussion 
Generalized gingival overgrowth can be caused by a number of factors including 
inflammation, leukemia, inheritance and drugs.28 The most common form is 
induced by drugs such as phenytoin, nifedipine and CyA.29 Despite extensive 
studies, the mechanism that leads to the accumulation of abnormal amounts of 
gingival tissue in CyA-induced gingival overgrowth is still unknown. The excess 
accumulation of connective tissue has traditionally been regarded to result from 
local increases in collagen synthesis, which is consistent with the histological 
characteristics of gingiva of patients with CyA-induced gingival overgrowth.30 
However, recent studies have recognized the equally important role of connective 
tissue degradation and resident cell proliferation in the pathogenesis of this side 
effect.31 Additionally, we have recently shown that elevated expression and 
production of TGF-(31 in CyA-treated NG fibroblasts is associated with reduced 
expression and activity leveis of matrix metalloproteinases, in particular MMP-1 
and MMP-2, the most important enzymes associated with the extracellular matrix 
degradation and remodeling.13 
We demonstrated in this study that CyA stimulates NG fíbroblast 
proliferation at the same concentration found in the serum of patients undergoing 
CyA treatment (human serum leveis range of 100-250 ng/ml).27 lnterestingly, CyA 
at similar doses utilized in this study signifícantly induces expression and synthesis 
of TGF-(31 by NG fíbroblasts.13 Addition of TGF-(31 signif1cantly affected NG 
fibroblast proliferation in a dose-dependent manner. Moreover, the studies 
presented here revealed that CyA stimulates NG fibroblast proliferation through 
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autocrine stimulation of TGF-~1, and that neutralization of CyA-treated NG 
fibroblast proliferation by specific TGF-~1 antisense oligonucleotides is reversed by 
the addition of exogenous TGF-~1. 
There are only a few and controversial previous studies demonstrating the 
proliferative response of NG fibroblasts to CyA. lncrease, decrease or absence of 
effect in the proliferation rates after different drug concentration treatments have 
been reported?2-36 Such variations among these studies may be attributed to 
subsets of fibroblasts that exist in gingiva and periodontum.37·38 These studies 
suggest that alterations of the gingival connective tissue may result from clonal 
imbalance of resident fibroblast subtypes rather than from the presence of altered 
cells. Furthermore, the relative proportions of various subtypes of fibroblasts and 
their functional activities in the tissue could be regulated by specific cellular 
interactions with molecules such as cytokines. Moreover, inter-individual 
susceptibility to CyA-induced gingival overgrowth may also be related to a genetic 
predisposition, including variations in drug responsiveness and tolerance.39.4° Our 
data showing the effect of CyA on the proliferation of NG fibroblasts are in 
agreement with various reports, including those of Bartold.33 This author has 
demonstrated that CyA stimulates DNA synthesis and proliferation of NG 
fibroblasts and that this ability is retained even in the presence of 
lipopolysaccharide (LPS) that would normally inhibit these cells. Furthermore, the 
same author used similar concentrations of CyA, demonstrating that the 
stimulatory effect on cell proliferation occurs within the concentration ranges found 
in plasma and tissue of patients taking CyA.27·41 
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TGF-[31 prometes wound healing in vivo not only by stimulating the 
production of other growth factor such as platelet-derived growth factors (PDGF), 
but also by upregulating the proliferation of fibroblasts.20.42 In the TGF-131 dose-
response analysis, low concentrations (0.1 and 1 ng/ml) were more efficient than 
higher concentrations (10 ng/ml). Although the leveis of response of these low 
concentrations were not significantly different from each other in this experiment, 
the relative leveis of response were consistent with those of the dose-response 
experiments suggesting a concentration-dependent effect. Previous studies have 
demonstrated that TGF-131 is a mitogen for the human periodontal ligament 
fibroblasts with a bimodal effect.43 This is in contrast to the results here presented 
using fibroblasts derived from normal gingiva. Although human periodontal 
ligament and gingival fibroblasts share common morphological features, it is not 
known how periodontal ligament fibroblasts compare to NG fibroblasts, and 
potential differences in these cell types may account for the distinct responses to 
growth factors such as TGF-131. Additionally, Dennison et al.21 demonstrated that 
the effect of 1 O ng/ml of TGF-131 on cell proliferation is different between 
periodontal ligament and NG fibroblasts. 
The studies presented here also revealed that CyA induces proliferation in 
NG fibroblasts via induction of TGF-131. The effect of CyA on NG proliferation was 
significantly reduced by blocking endogenous production of TGF-131. Furthermore, 
our data suggested that the TGF-131 signaling pathways are not compromised by 
the treatment with oligonucleotides, since exogenous TGF-131 reversed the effects 
of the antisense oligonucleotides. TGF-131 is the prototype of the TGF-13 
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superfamily of multifunctional peptides that control cell proliferation, differentiation 
and other functions in many cell types.44 TGF-~1 has a profound growth inhibitory 
effect in cultured keratinocytes. On the other hand, TGF-~1 enhances fibroblast 
proliferation, not only by increasing the G1/S transition and DNA synthesis, but also 
by shortening the G1 phase of the cell cycle.45 Although recent studies have 
delineated the binding of TGF-~1 to different serine-threonine receptor subtypes, 
little is known about its exact signaling pathways.46 Various elements responsible 
for TGF-~1 gene induction have been identified, including phorbol myristate 
acetate (PMA), cAMP and AP-1.47.48 Although calcineurin substrates, also known 
as phosphatase 2B (PP2B), are not yet clearly identified, it has been suggested 
that dephosphorylation of the Rll regulatory subunit of protein kinase A by PP2B 
could be a mechanism by which ca+2 increases the rate of inactivation of protein 
kinase A.49 Van der Pouw Kraan50 demonstrated that CyA enhanced the 
production of IL-13 from T-lymphocytes stimulated with anti-CD3 antibodies. This 
observation was comparable to the one obtained with PMA in the same conditions 
leading to the hypothesis that protein kinase C activation is responsible for the 
positive regulation of IL-13 production whereas Ca+2 mobilization has a negative 
effect. Thus, it can be hypothesized that inhibition of calcineurin with CyA could 
avoid the negative regulatory effect of this calcium-dependent phosphatase on 
cAMP/protein kinase A or protein kinase C-mediated TGF-~1 promoter activity 
leading to an enhancement of TGF-)31 gene transcription and stimulation of cell 
proliferation. However, additional work is required to better understand the 
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downstream events triggered by CyA on proliferative stimulation of NG fibroblasts 
via TGF-~1. 
In summary, we have demonstrated that enhanced proliferation of CyA-
treated gingival fibroblasts is mediated by TGF-~1 autocrine stimulation. Recently, 
our investigations of the molecular events that lead to CyA-induced gingival 
overgrowth showed a stimulation of TGF-~1 expression and production, which is 
associated, in an autocrine fashion, with a dowregulation of MMP-1 and MMP-2.13 
Furthermore, TGF-~1 upregulates type I collagen expression in fibroblasts from 
normal and hereditary gingival fibromatosis gingiva.51 Taken together, our data 
suggest that TGF-~1 is a key regulator of the biochemical mechanisms associated 
in the pathogenesis of gingival overgrowth induced by CyA. The mechanisms 
involved in CyA inducing gingival overgrowth will be better understood when 
clinicai, microscopic and microbiological data are considered in conjunction with 
new molecular techniques that are becoming available. 
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